Amylin Pharmaceuticals, Inc. (AMLN)

  • Nasdaq: AMLN
  • Mkt.Cap.:3.09B
Focused: Healthcare > Biopharmaceuticals > Endocrinology/Metabolism > Diabetes (^228079)

Classification

Sector
Healthcare
Biopharmaceuticals
Endocrinology/Metabolism

The Endocrinology/Metabolism Subsector includes therapeutics that treat metabolic disorders and conditions resulting from the dysfunction of hormone secreting glands.

- Focused
- Sector Pure-Play

Sector companies

Top 3 competitive companies in Diabetes (^228079) :

Ticker Name Mkt.Cap.
NVO Novo Nordisk A/S (ADR) 54.81B
BIOD Biodel Inc 104.78M
CJB:CA ConjuChem Biotechnologies Inc. 18.78M

Relationships

Sample 8 relationships grouped by relationhip type.

Ticker Name
Competitors
Defined by the Company ABT Abbott Laboratories
Defined by the Company BMY Bristol Myers Squibb Co.
Customers
Defined by the Company CAH Cardinal Health, Inc.
Defined by the Company LLY Eli Lilly & Co.
Suppliers
Defined by the Company ALKS Alkermes, Inc.
Defined by the Company AMGN Amgen, Inc.
Partners
Defined by the Company ALKS Alkermes, Inc.
Defined by the Company AMGN Amgen, Inc.
- Defined by the Company
- Defined by Others

Products & Services

Sample products & services from Diabetes (^228079) :

  • Bydureon (Exenatide LAR)
  • Byetta (Exenatide)
  • Davalintide/Formerly AC2307

Relative Performance (1Y)

Relative Chart
  • - Amylin Pharmaceuticals, Inc. (AMLN)
  • - S&P 500 INDEX (SPX)
  • - Healthcare > Biopharmaceuticals > Endocrinology/Metabolism > Diabetes (^228079)

Subscribe to an RSS Feed Research Reports

more »